Patents by Inventor Sandrine V. Pierre

Sandrine V. Pierre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for treating pulmonary hypertension
    Patent number: 11220528
    Abstract: Methods treating pulmonary hypertension, including pulmonary arterial hypertension, are provided, and include administering a polypeptide antagonist of a Na/K ATPase/Src receptor complex to a subject in need thereof. Administration of the polypeptide antagonist reduces pulmonary artery acceleration time, reduces an amount of right ventricular hypertrophy, reduces right ventricular wall thickness, reduces an amount of pulmonary vessel wall thickness, reduces an amount of plexiform lesions in a lung of the subject, reduces an amount of collagen deposition in a pulmonary blood vessel, reduces an amount of collagen deposition in a pulmonary blood vessel media or adventitia, and/or reduces an amount of right ventricular fibrosis. Methods of reducing pulmonary vessel wall thickness are also provided and include the administration of the polypeptide antagonist of a Na/K ATPase/Src receptor complex.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: January 11, 2022
    Assignee: MARSHALL UNIVERSITY RESEARCH CORPORATION
    Inventors: Zijian Xie, Jiayan Wang, Sandrine V. Pierre, Joseph I. Shapiro
  • COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION
    Publication number: 20200165299
    Abstract: Methods treating pulmonary hypertension, including pulmonary arterial hypertension, are provided, and include administering a polypeptide antagonist of a Na/K ATPase/Src receptor complex to a subject in need thereof. Administration of the polypeptide antagonist reduces pulmonary artery acceleration time, reduces an amount of right ventricular hypertrophy, reduces right ventricular wall thickness, reduces an amount of pulmonary vessel wall thickness, reduces an amount of plexiform lesions in a lung of the subject, reduces an amount of collagen deposition in a pulmonary blood vessel, reduces an amount of collagen deposition in a pulmonary blood vessel media or adventitia, and/or reduces an amount of right ventricular fibrosis. Methods of reducing pulmonary vessel wall thickness are also provided and include the administration of the polypeptide antagonist of a Na/K ATPase/Src receptor complex.
    Type: Application
    Filed: May 11, 2018
    Publication date: May 28, 2020
    Inventors: Zijian Xie, Jiayan Wang, Sandrine V. Pierre, Joseph I. Shapiro